“Our team at BluMetric continues to deliver excellent results, putting the Company in a solid position to focus on future growth as economic activity continues to ramp up,“ says Scott MacFabe, CEO of BluMetric. […]
PHILADELPHIA, PA / ACCESSWIRE / July 29, 2021 / Pennexx Foods (OTC PINK:PNNX) Vincent Risalvato, CEO of Pennexx, conducted an interview where he talks about the updated launch of https://YourSocialOffers.com, its second quarter of profitability, its goals […]
Interview Update with David Chen, President and CEO […]
FARMINGTON HILLS, Mich., June 11, 2021 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on development and commercialization of therapies for the treatment of several eye disorders, today announced […]
Newly Issued Claims Extend Patent Protection to Year 2039 for Nyxol®Combination Therapy for Presbyopia […]
Launch of Psychedelics DNA Test Kit,
Phase 1 clinical trial for DMT progressing as planned,
Pre-clinical In Vivo work scheduled to start at Israeli CRO […]
Reported Positive Data in First Pivotal Phase 3 Trial for Nyxol Eye Drops with Plans to Advance Towards NDA Submission and Commercialization in Reversal of Mydriasis Indication […]
● Compositions and Methods for Enhancing Anti-viral Therapies ●
[…]
Interview with Timothy Ko, CEO […]
Copyright © 2019 The Wall Street Analyst, LLC. All rights reserved. Website by MyWebsiteSpot.com